Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (WO2018098553) PRODUCTION D'ANTICORPS DE RICIN DANS UNE PLANTE
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

CLAIMS:

1. A method of making an antibody or antibody fragment in a plant that binds to ricin B chain comprising:

(a) introducing a nucleic acid molecule encoding a heavy chain variable region of the antibody and a nucleic acid molecule encoding a light chain variable region of the antibody into a plant or plant cell; and

(b) growing the plant or plant cell to obtain a plant that expresses the antibody or antibody fragment.

2. A method according to claim 1 , further comprising introducing a nucleic acid molecule encoding P19 suppressor of gene-silencing protein into the plant or plant cell.

3. A method according to claim 1 or 2, further comprising introducing a nucleic acid molecule encoding human 1 ,4-galactosyltransferase (GalT) into the plant or plant cell.

4. A method according to any one of claims 1 -3, wherein the nucleic acid molecule encoding the heavy chain variable region and the nucleic acid molecule encoding the light chain variable region of the antibody are introduced on the same vector.

5. A method according to claim 4, wherein the nucleic acid molecule encoding the heavy chain variable region and the nucleic acid molecule encoding the light chain variable region of the antibody are adjacent to each other in the vector in opposite and divergent transcriptional orientations.

6. A method according to any one of claims 1 -5, wherein the nucleic acid molecule encoding the heavy chain variable region comprises a Complementarity Determining Region (CDR) H1 sequence as shown in SEQ ID NO:2, a CDR H2 sequence as shown in SEQ ID NO:3, and/or a CDR H3 sequence as shown in SEQ I D NO:4.

7. A method according to any one of claims 1 -6, wherein the heavy chain variable region comprises the amino acid sequence of CDR H1 as shown in SEQ ID NO:6, CDR H2 as shown in SEQ ID NO:7, and/or CDR H3 as shown in SEQ ID NO:8.

8. A method according to any one of claims 1 -7, wherein the nucleic acid molecule encoding the light chain variable region comprises a CDR L1 sequence as shown in SEQ ID NO: 10, a CDR L2 sequence as shown in SEQ ID NO: 1 1 , and/or a CDR L3 sequence as shown in SEQ ID NO: 12.

9. A method according to any one of claims 1-8, wherein the light chain variable region comprises the amino acid sequence of CDR L1 as shown in

SEQ ID NO: 14, CDR L2 as shown in SEQ ID NO: 15, and/or CDR L3 as shown in SEQ ID NO: 16.

10. A method according to any one of claims 1 -9, wherein the nucleic acid molecule encoding the heavy chain variable region comprises a sequence as shown in SEQ ID NO: 1 , or a sequence at least 75% identical to SEQ ID NO: 1 or the framework region thereof.

1 1 . A method according to any one of claims 1 -10, wherein the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:5, or a sequence at least 75% identical to SEQ I D NO:5 or the framework region thereof.

12. A method according to any one of claims 1 -1 1 , wherein the nucleic acid molecule encoding the light chain variable region comprises a sequence as shown in SEQ ID NO:9, or a sequence at least 75% identical to SEQ ID NO:9 or to the framework region thereof.

13. A method according to any one of claims 1 -12, wherein the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO: 13, or a sequence at least 75% identical to SEQ I D NO: 13 or the framework region thereof.

14. A method according to any one of claims 1 to 13, wherein the plant is N. benthamiana.

15. A method according to any one of claims 1 to 14, wherein the antibody or antibody fragment is purified and polished by contacting the antibody or antibody fragment with Butyl HP resin.

16. An antibody or antibody fragment prepared according to the method of any one of claims 1 to 15.

17. The antibody of claim 16, wherein the antibody is an lgG1 antibody.

18. The antibody or antibody fragment of claim 16 or 17, wherein the antibody or antibody fragment comprises a humanized glycosylation profile.

19. A composition comprising the antibody or antibody fragment of any one of claims 1 to 18 and a pharmaceutically acceptable diluent, excipient, or carrier.

20. The composition of claim 19, wherein the composition is a vaccine composition.

21 . A method of preventing deleterious effects caused by ricin exposure or of treating exposure to ricin, comprising administering the antibody or antibody fragment of any one of claims 1 to 18 or the composition of claim 19 or 20 to a subject in need thereof.

22. The method of claim 21 , wherein the subject is a mouse, rat, a non-human primate, or a human.

23. The method of claim 21 or 22, wherein the antibody or antibody fragment is administered to the subject several hours following exposure to ricin to treat ricin exposure.

24. The method of any one of claims 21 to 23, wherein the antibody or antibody fragment is administered to the subject several days or weeks prior to exposure to the ricin toxin to protect the subject against ricin exposure.

25. A transgenic plant or plant cell that expresses an antibody that binds to ricin B chain comprising a nucleic acid molecule encoding a heavy chain variable region of the antibody, and a nucleic acid molecule encoding a light chain variable region of the antibody.

26. The transgenic plant or plant cell of claim 25, wherein the plant or plant cell further comprises a nucleic acid molecule encoding the P19 suppressor of gene-silencing protein and a nucleic acid molecule encoding human GalT.

27. The transgenic plant or plant cell of claim 25 or 26, wherein the heavy chain variable region comprises a CDR H1 sequence as shown in SEQ ID NO:6, a CDR H2 sequence as shown in SEQ ID NO:7, and/or a CDR H3 sequence as shown in SEQ ID NO:8; and the light chain variable region comprises a CDR L1 sequence as shown in SEQ ID NO: 14, a CDR L2 sequence as shown in SEQ ID NO: 15, and/or a CDR L3 sequence as shown in SEQ ID NO: 16.